A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme

A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa™) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme

The purpose of the study is to determine the efficacy of gefitinib (IressaTM) in combination with radiotherapy on patients with glioblastoma multiforme.

Inclusion Criteria:

• Signed informed consent
• histologically-or cytologically-confirmed glioblastoma multiforme
• age 18 years or older

Exclusion Criteria:

• Have had prior radiation therapy, immunotherapy, gene therapy and/or chemotherapy for the glioblastoma
• co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ
• known severe hypersensitivity to ZD1839 or any of the excipients of this product.